India, July 15 -- SELLAS Life Sciences Group, Inc. (SLS) Tuesday said that its Phase 2 trial of SLS009 in patients with relapsed/refractory acute myeloid leukemia (r/r AML) met all primary goals.
The Phase 2 study was designed to evaluate SLS009 in combination with venetoclax and azacitidine. The primary endpoint for the trial was overall response rate (ORR). The study exceeded target ORR of 20% with 44% response rate in patients with Acute Myeloid Leukemia-Myelodysplasia-Related Changes (AML MR). Median Overall Survival (mOS) was 8.9 Months, which surpassed the historical median of 2.4 months.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843-0'); });
The FDA has recommended SELLAS to include newly diagnosed, f...